Changes of osteoprotegeria before and after insulin therapy in type 1 diabetic patients

National Medical Journal of China

Volumn 87, Issue 18, 2007, Pages 1234-1237

  Xiang, Guang Da ^a   Sun, Hui Ling ^a   Zhao, Lin Shuang ^a   Hou, Jie ^a   Yue, Ling ^a   Xu, Lin ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Diabetes mellitus; Endothelium; Insulin dependent; Osteoprotegeria; Vascular

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; INSULIN; OSTEOPROTEGERIN; ANTIDIABETIC AGENT; LIPID;

ADOLESCENT; ADULT; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPEREMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; MULTIVARIATE ANALYSIS; PROTEIN BLOOD LEVEL; REST; SCHOOL CHILD; TREATMENT DURATION; VASCULAR ENDOTHELIUM; BLOOD; CHILD; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; TREATMENT OUTCOME; VASODILATATION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BRACHIAL ARTERY; CHILD; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; OSTEOPROTEGERIN; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 34447552665     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319.
2. Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS letters, 2002, 521: 180-184.
3. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002, 106: 1192-1194.
4. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 2003, 88: 1024-1028.
5. Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol, 2003, 149: 39-42.
6. Avignon A, Sultan A, Piot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care, 2005, 28: 2176-2180.
7. Galluzzi F, Stagi S, Salti R, et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol, 2005, 153: 879-885.
8. Xiang GD, Wu YH. Apolipoprotein e4 allele and endothelium-dependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 2003, 46: 514-519.
9. Xiang GD, Wang YL, Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care, 2004, 27: 801-802.
10. Xiang GD, Xu L, Zhao LS, et al. The Relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. Diabetes, 2006, 55: 2126-2131.
11. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arteriosclerosis, Thrombo, Vascul Biol, 2001, 21: 1998-2003.
12. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Devel, 1998, 12: 1260-1268.
13. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Bio Chem, 2000, 275: 20959-20962.
14. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab, 2001, 86: 631-637.
15. Ueland T, Jemtland R, Godang K, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J American College Cardiol, 2004, 44: 1970-1976.
16. Rasmussen LM, Tarnow L, Hansen TK, et al. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol, 2006, 154: 75-81.
17. Chinese source.
18. Kim SM, Leet J, Ryu OH, et al. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol, 2005, 63: 594-598.
19. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation, 2004, 109: 2175-2180.
20. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. JACC, 1999, 34: 146-154.
21. Cosson E, Pham I, Valens P, et al. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in type 2 diabetes and angiographically normal coronary arteries. Diabetes Care, 2006, 29: 107-112.